Skip to content

Advertisement

  • Research article
  • Open Access

PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome

  • 1,
  • 1,
  • 1, 2,
  • 2,
  • 1, 3,
  • 3,
  • 4,
  • 4,
  • 5,
  • 5,
  • 1, 6,
  • 1, 7, 8, 9 and
  • 1, 9, 10Email authorView ORCID ID profile
Infectious Agents and Cancer201813:43

https://doi.org/10.1186/s13027-018-0216-3

©  The Author(s). 2018

  • Received: 27 July 2018
  • Accepted: 5 December 2018
  • Published:

Abstract

Background

Chronic diseases such as chagasic megaesophagus (secondary to Chagas’ disease) have been suggested as etiological factors for esophageal squamous cell carcinoma; however, the molecular mechanisms involved are poorly understood.

Objective

We analyzed hotspot PIK3CA gene mutations in a series of esophageal squamous cell carcinomas associated or not with chagasic megaesophagus, as well as, in chagasic megaesophagus biopsies. We also checked for correlations between the presence of PIK3CA mutations with patients’ clinical and pathological features.

Methods

The study included three different groups of patients: i) 23 patients with chagasic megaesophagus associated with esophageal squamous cell carcinoma (CM/ESCC); ii) 38 patients with esophageal squamous cell carcinoma not associated with chagasic megaesophagus (ESCC); and iii) 28 patients with chagasic megaesophagus without esophageal squamous cell carcinoma (CM). PIK3CA hotspot mutations in exons 9 and 20 were evaluated by PCR followed by direct sequencing technique.

Results

PIK3CA mutations were identified in 21.7% (5 out of 23) of CM/ESCC cases, in 10.5% (4 out of 38) of ESCC and in only 3.6% (1 case out of 28) of CM cases. In the CM/ESCC group, PIK3CA mutations were significantly associated with lower survival (mean 5 months), when compared to wild-type patients (mean 2.0 years). No other significant associations were observed between PIK3CA mutations and patients’ clinical features or TP53 mutation profile.

Conclusion

This is the first report on the presence of PIK3CA mutations in esophageal cancer associated with chagasic megaesophagus. The detection of PIK3CA mutations in benign chagasic megaesophagus lesions suggests their putative role in esophageal squamous cell carcinoma development and opens new opportunities for targeted-therapies for these diseases.

Keywords

  • Esophageal cancer
  • Trypanosoma cruzi
  • Achalasia
  • Esophageal squamous cell carcinoma
  • Chagasic megaesophagus
  • PIK3CA
  • Mutation

Introduction

Esophageal cancer is the eighth most frequent type of cancer in the world and the sixth most lethal, occurring mainly in developing countries such as Brazil [1]. The most frequent histological subtype is esophageal squamous cell carcinoma (ESCC), accounting for 90% of cases, especially in high-risk areas [2]. The main risk factors for ESCC are alcohol consumption, tobacco (mainly in association) and hot-beverage consumption [3]. It is also reported that chronic diseases, such as the chagasic megaesophagus, can be associated with ESCC development [4].

Chagasic megaesophagus is the late manifestation of Chagas’ disease (caused by the protozoan Trypanosoma cruzi) [5]. Direct infection of Trypanosoma cruzi will lead to destruction of the intramural myenteric neurons in the esophagus, causing inflammation and production of neurotoxins. This will result in uncoordinated contractions and reduction of peristalsis of the organ, altering the functioning of the lower esophageal sphincter and progressive dilation of the esophagus (megaesophagus) [6]. In Brazil, one of the endemic regions of Chagas’ disease, approximately 4 million people are infected with the parasite and about 6–7% of these patients will develop chagasic megaesophagus [5]. Patients affected with this lesion are more likely to develop ESCC (3–10%) when compared to the general population [4].

The carcinogenic mechanisms of ESCC development in the context of chagasic megaesophagus have been little explored. Recently, our group showed the high frequency (13/32, 40.6%) of TP53 mutations in ESCC associated with chagasic megaesophagus [7]. Moreover, we also reported the presence of microsatellite instability (MSI) in a small fraction (1/19, 5.3%) of cases [8]. However, many other genes are known to be involved in ESCC carcinogenesis as demonstrated by the TCGA consortium [9].

One of these genes is the PI3KCA, which encodes the protein phosphatidylinositol 3-kinase (PI3K), that belongs to a family of lipid kinases that encodes the p110α catalytic subunit [10]. PI3K is a quite complex signaling pathway since it regulates cell growth, proliferation, cell motility, the production of new proteins, apoptosis and cell survival [10]. Therefore, its activation will lead to many downstream pathways that regulate several cellular functions, including those involved in the development of cancer [10, 11]. Recurrent PI3KCA oncogenic mutations were identified in several types of tumors, including colorectal, breast, ovary, gastric, and recently in ESSC [12]. The mutations occur mainly in exons 9 (E542K and E545K) and 20 (H1047R) [12]. Recently, it was shown that PIK3CA mutations, namely H1047R, also disrupt cellular genetic stability, increasing the frequency of chromosomal errors and leading to tetraploidy [13]. Importantly, therapeutic strategies targeting the PIK3/Akt signaling pathway have been developed and could constitute effective treatment options for patients harboring PI3KCA mutations [14].

Therefore, in the current study we performed the mutation analysis of PIK3CA gene in patients with ESCC and chagasic megaesophagus associated or not with ESCC, and searched for associations between the mutation status and patients’ clinical and pathological features.

Materials and methods

Study population

In this retrospective study, we analyzed 89 formalin-fixed paraffin-embedded (FFPE) tissues of three groups of patients: i) 23 patients with chagasic megaesophagus associated with esophageal squamous cell carcinoma (CM/ESCC); ii) 38 patients with esophageal squamous cell carcinoma without chagasic megaesophagus (ESCC); and iii) 28 patients with chagasic megaesophagus without esophageal squamous cell carcinoma (CM). All chagasic megaesophagus patients were serologic positive for Chagas’ disease and/or had exams (imaging and histopathology) that confirmed the presence of megaesophagus. The patients with esophageal squamous cell carcinoma without chagasic megaesophagus were all serologic negative for Chagas’ disease and had exams (imaging and histopathology) that confirmed malignant disease. These patients were previously described for their clinical-pathological and molecular TP53 and MSI features [7, 8].

The samples were obtained from patients treated between 1990 and 2016 in three different institutions from the Southeast of Brazil, namely: Barretos Cancer Hospital, Barretos, São Paulo State; Federal University of Triângulo Mineiro (UFTM), Uberaba, Minas Gerais State and São Paulo State University (UNESP), Botucatu, São Paulo State. All clinical and pathological information was obtained through medical record review.

DNA isolation

Following tissue macro-dissection, DNA was isolated from FFPE tissue representative of the tumor lesions in ESCC and CM/ESCC groups and esophageal tissues in CM group, as previously described [7]. Briefly, the tumor area was delineated in a hematoxylin-eosin stained (HE, Merck KGaA, GE) section by a pathologist, and the marked area was scraped by scalp from 3 to 5 10 μm unstained slides into a 1,5 ml tube. Afterwards, the tissue was subjected to the dewaxing step by heating (80 °C – 20 min), followed by sequential washing in xylol (5 min) and decreasing concentrations of ethanol (1 min - 100, 70 and 50%) and nuclease-free water9 (1 min). DNA isolation was performed using the QIAamp DNA Micro Kit (Qiagen) following the manufacture’s protocol.

PIK3CA mutation analysis

Polymerase chain reaction (PCR) followed by direct sequencing (Sanger method) was performed for the analysis of hotspot mutations (exons 9 and 20) of the PIK3CA gene as previously described [15]. The PCR was performed on the 89 samples under the following conditions: 5X Flexi Buffer (pH 8.5) and 25 mM MgCl2 (Promega, USA), 200 μM dNTPmix (Invitrogen, USA), 200 nM primers exon 9 (forward 5’-CTGTGAATCCAGAGGGGAAA-3′ and reverse 5’-ACATGCTGAGATCAGCCAAAT-3′) and exon 20 (forward 5’-ATGATGCTTGGCTCTGGAAT-3′ and reverse 5’-GGTCTTTGCCTGCTGAGAGT-3′), 1.25 U GoTaq®Hot Start Polymerase (Promega, USA), and nuclease-free water (Gibco, BRL, Life Technologies, USA) in a final volume of 25 μl and 5 μl of DNA at 50 ng/μl from each patient were added [15]. Amplification was performed in a thermocycler according to the protocol: 96 °C for 15 min, followed by 40 cycles at 96 °C for 45 s, 55.5 °C for 45 s and 72 °C for 45 s and final extension of 72 °C for 10 min, followed by a hold at 4 °C. PCR products were subjected to 1.5% agarose gel electrophoresis with Gel Red (Biotium, Hayward, CA) to evaluate the amplification of the gene of interest.

After agarose gel validation, we purified the preparation using the enzyme ExoSap-IT (GE Technology, Cleveland, USA), followed by the sequencing reaction using BigDye Terminator v3.1 (Applied Biosystems, USA) and 3.2 μM of specific primers and re-purified with xTerminator (Life Technology). The products were sequenced using the 3500 series Genetic Analyzer Capillary Sequencer (Applied Biosystems, USA). All the cases that showed mutations were confirmed with a new PCR reaction and direct sequencing.

Statistical analysis

Characterization of the study population was performed through frequency tables for qualitative variables, and measures of central tendency and dispersion (mean, standard deviation, minimum and maximum) for the quantitative variables, comparing the different groups. To verify the association between PIK3CA mutation status and clinical groups, pathological and molecular features, Chi-square or Fisher’s exact tests were applied. We performed an overallsurvival analysis using the Kaplan-Meier limit estimator and the Log-rank test to compare the survival curves between the groups.

The level of significance adopted was 5% (p ≤ 0.05). Statistical analyzes were in SPSS software v.21.0.

Results

Characterization of the population

The clinical-pathological characteristics of the patients in the three groups are described in Table 1. The mean age of the patients was higher in the chagasic groups (Table 1). As already reported in our previous studies [7], concerning risk factors for esophageal cancer, the ESCC and CM/ESCC groups were statistically associated with higher tobacco and alcohol consumption (Table 1).
Table 1

The clinical-pathological features of the three groups of patients

Variable

 

Groups (n = 89)

 

Category

CM/ESCC (n = 23)

ESCC (n = 38)

CM (n = 28)

p-value

Gender

Female

4 (17.4%)

7 (18.4%)

4 (14.3%)

0.937**

Male

19 (82.6%)

31 (81.6%)

24 (85.7%)

Age (years)

Mean (SD)

59 (11)

57 (9)

59 (11)

0.039 ***

Min - Max

37–76

36–75

37–76

Alcohol consumption

No

7 (31.8%)

8 (21.1%)

20 (71.4%)

< 0.001 *

Yes

15 (68.2%)

30 (78.9%)

8 (28.6%)

Missing

11

0

0

 

Tobacco consumption

No

4 (18.2%)

6 (15.8%)

16 (57.1%)

< 0.001 *

Yes

18 (81.8%)

32 (84.2%)

12 (42.9%)

Missing

1

0

0

 

Tumor differentiation

Well differentiated

5 (22.7%)

7 (19.4%)

NA

0.639**

Moderate differentiated

16 (72.7%)

24 (66.7%)

NA

Poorly differentiated

1 (4.5%)

5 (13.9%)

NA

Missing

1

2

NA

 

TNM Staging

I/II

4 (23.5%)

16 (42.1%)

NA

0.235*

III/IV

13 (76.5%)

22 (57.9%)

NA

Missing

6

0

NA

 

Megaesophagus grades

GI/GII

10 (45.5%)

NA

4 (14.3%)

0.025 *

GIII/GIV

12 (54.5%)

NA

24 (85.7%)

Missing

1

NA

0

 

*Chi-square association test; **Fisher’s exact test; ***Analysis of variance. CM/ESCC – chagasic megaesophagus associated with esophageal squamous cell carcinoma; ESCC – esophageal squamous cell carcinoma without chagasic megaesophagus; CM – chagasic megaesophagus without esophageal squamous cell carcinoma; SD - standard deviation; NA – not applicable; Bold numbers - statistical significance 

Mutation analysis of PIK3CA gene

The PIK3CA mutation analysis showed the presence of mutations in 21.7% of patients in CM/ESCC group, followed by 10.5% in ESCC group and 3.6% in CM group (Fig. 1 and Table 2). The frequency of mutations was similar in exons 9 and 20 (Table 3). With the exception of three variants (A1027D, K1030R and T1053K), all the other mutations have already been reported in the Catalogue of Somatic Mutations in Cancer database – COSMIC (http://cancer.sanger.ac.uk/cosmic) (Fig. 2 and Table 3).
Fig. 1
Fig. 1

Electropherogram of PIK3CA gene. Exon 9 – wild-type sequence and mutated sequence (D549H). Exon 20 – wild-type sequence and mutated sequence (H1047R)

Table 2

Frequency of PIK3CA mutations in the three study groups

Variable

 

Groups (n = 89)

 

Category

CM/ESCC (n = 23)

ESCC (n = 38)

CM (n = 28)

p-value

PIK3CA gene

WT

18 (78.3%)

34 (89.5%)

27 (96.4%)

0.132**

MUT

5 (21.7%)

4 (10.5%)

1 (3.6%)

**Fisher’s exact test. CM/ESCC – chagasic megaesophagus associated with esophageal squamous cell carcinoma; ESCC – esophageal squamous cell carcinoma without chagasic megaesophagus; CM – chagasic megaesophagus without esophageal squamous cell carcinoma. WT – wild-type; MUT – mutant; N – number of cases

Table 3

Profile of oncogenic PIK3CA mutations in the three study groups

Group

Sample ID

Exon

Codon

Codon (WT – MUT)

Type of mutation

Amino acids change

Nature of mutation

COSMIC ID

CM/ESCC

111 T

9

545

GAG – GCA

A → C

E545A

Missense

COSM12458

122 T

9

549

GAT – CAT

G → C

D549H

Missense

COSM219119

114 T

20

1027

GCC – GAC

C → A

A1027D

Missense

Not reported

119 T

20

1047

CAT – CTT

A → T

H1047L

Missense

COSM776

124 T

20

1047

CAT–CGT

A → G

H1047R

Missense

COSM775

ESCC

26 T

9

545

GAG – GCG

A → C

E545A

Missense

COSM12458

120 T

9

555

AGG – AAG

G → A

R555K

Missense

COSM1716158

36 T

9

524

AGG – AAG

G → A

R524K

Missense

COSM53245

4 T

20

1030

AAA – AGA

A → G

K1030R

Missense

Not reported

CME

101 M

20

1053

ACA – AAA

C → A

T1053K

Missense

Not reported

CME/ESCC – chagasic megaesophagus associated with esophageal squamous cell carcinoma; ESCC – esophageal squamous cell carcinoma without chagasic megaesophagus; CME – chagasic megaesophagus without esophageal squamous cell carcinoma. A – adenine; C – cytosine; G – guanine; T – thymine. WT – wild-type; MUT – mutant

Fig. 2
Fig. 2

PIK3CA protein and missense mutation overview

No significant associations were observed between the PIK3CA mutation status and patients pathological features (Table 4). Furthermore, we assessed the role of PIK3CA mutations on patients’ overall survival in both groups affected by cancer (CM/ESCC and ESCC) (Fig. 3). In CM/ESCC group, we observed that the presence of PIK3CA mutations was significantly associated with a lower survival rate from the diagnosis of cancer compared to wild-type patients (Fig. 3a). The mean patients’ overall survival in cases from the CM/ESCC group mutated for the PIK3CA was 5 months, in comparison with 2.0 years for wild-type PIK3CA patients (Log-rank, p < 0.001) (Table 5).
Table 4

Association between PIK3CA mutation status with main clinical-pathological features in the three groups

Variable

 

PIK3CA gene

 

CM/ESCC group

 

ESCC group

 

CM group

 

Category

WT

MUT

p-value

WT

MUT

p-value

WT

MUT

p-value

Alcohol consumption

No

6 (35.3%)

1 (20%)

1.000**

7 (21.2%)

1 (20%)

1.000**

19 (70.4%)

1 (100%)

1.000**

Yes

11 (64.7%)

4 (80%)

26 (78.8%)

4 (80%)

8 (29.6%)

0 (0%)

Tobacco consumption

No

4 (23.5%)

0 (0%)

0.535**

5 (15.2%)

1 (20%)

1.000**

15 (100%)

1 (100%)

1.000**

Yes

13 (76.5%)

5 (100%)

28 (84.8%)

4 (80%)

12 (44.4%)

0 (0%)

Tumor differentiation

Well

4 (22.2%)

1 (25%)

1.000**

7 (22.6%)

0 (0%)

0.171**

NA

NA

NA

Moderate

13 (72.2%)

3 (75%)

21 (67.7%)

3 (60%)

NA

NA

Poorly

1 (5.6%)

0 (0%)

3 (9.7%)

2 (40%)

NA

NA

TNM Staging

I e II

4 (28.6%)

0 (0%)

0.541**

15 (46.9%)

1 (20%)

0.421**

NA

NA

NA

III e IV

10 (71.4%)

3 (100%)

17 (53.1%)

4 (80%)

NA

NA

Megaesophagus degree

GI/GII

7 (41.2%)

3 (60%)

0.406**

NA

NA

NA

3 (11.1%)

1 (100%)

0.143**

GIII/GIV

10 (58.8%)

2 (40%)

NA

NA

24 (88.9%)

0 (0%)

TP53 gene [7]

WT

9 (50%)

2 (40%)

1.000**

20 (60.6%)

2 (40%)

0.632**

26 (96.3%)

1 (100%)

1.000**

MUT

9 (50%)

3 (60%)

13 (39.4%)

3 (60%)

1 (3.7%)

0 (0%)

**Fisher’s exact test; ***Analysis of variance. CME/ESCC – chagasic megaesophagus associated with esophageal squamous cell carcinoma; ESCC – esophageal squamous cell carcinoma without chagasic megaesophagus; CME – chagasic megaesophagus without esophageal squamous cell carcinoma. N – number of cases; SD – standard deviation; NA – not applicable; WT – wild-type; MUT – mutated

Fig. 3
Fig. 3

Cumulative survival of patients associated with the PIK3CA gene status. The red curves represent patients with mutation and the blue curves represent wild-type patients. a CM/ESCC – chagasic megaesophagus associated with squamous cell carcinoma of the esophagus; b ESCC – squamous cell carcinoma of the esophagus; MUT – mutant; WT – wild-type

Table 5

The time and average of patients’ overall survival according to PIK3CA mutation status

Groups

   

Time

  

Variable

Total

N events

6 months

1 year

3 years

5 years

Median survival

p-value

CM/ESCC

WT

13

10

79.4%

72.2%

43.3%

28.9%

2 years

< 0.001 *

MUT

5

5

20.0%

0.0%

0.0%

0.0%

5 months

ESCC

WT

24

22

82.6%

64.7%

32.6%

14.5%

2 years

0.405

MUT

4

4

80.0%

80.0%

60.0%

0.0%

2.5 years

*Log-rank test. CM/ESCC – chagasic megaesophagus associated with esophageal squamous cell carcinoma; ESCC – esophageal squamous cell carcinoma without chagasic megaesophagus; WT – wild-type; MUT – mutated; Bold numbers - statistical significance

Additionally, we evaluated the association of PIK3CA and TP53 mutation status, and no association was found (Table 4).

Discussion

Among the several risk factors for the development of ESCC, the chagasic megaesophagus (late complication of Chagas’ disease) has been a minor etiological factor and little explored [4]. Nevertheless, Chagas’ disease is still an important public health problem, particularly in Latin-America, where approximately 20 million people are infected with Chagas’ disease and approximately 6–7% of these people will develop chagasic megaesophagus [5, 16].

In the present study, we investigated the frequency of PIK3CA mutations in regions of hotspot (exons 9 and 20) in patients with chagasic megaesophagus associated with esophageal squamous cell carcinoma (CM/ESCC) and compared with patients with esophageal squamous cell carcinoma without chagasic megaesophagus (ESCC) and patients with chagasic megaesophagus without esophageal squamous cell carcinoma (CM). We observed that patients in the CM/ESCC group had a higher frequency of mutations (5/23, 21.7%) followed by patients in the ESCC group (4/38, 10.5%), and in the CM group (1/28, 3.6%). This is the first report of PIK3CA mutation in ESCC that developed in the context of chagasic megaesophagus and the significant frequency of mutations (~ 22%) suggest that PIK3CA plays an important role in the carcinogenesis of CM/ESCC patients. Moreover, the presence of PIK3CA mutation in a benign lesion further supports the putative role of chagasic megaesophagus as an ESCC-related condition. The frequency of mutations identified in our study is in line with that reported in the literature for ESCC patients, with frequencies varying from 2.2 to 32.8% (Table 6) [9, 17–33]. This variation can be due to several factors, such as type of tissue (frozen vs FFPE), distinct methodologies for mutation screening and distinct ethnic groups of patients. (Table 6).
Table 6

Frequency of PIK3CA mutations identified in patients with esophageal squamous cell carcinoma worldwide

References

Year

Country (Region)

Patients of study

PIK3CA mutated (%)

Type of sample

Techniques

Mori et al. [24]

2008

Japan

88

2.2%

FT

Direct Sequencing

Wang et al. [30]

2013

China

76

3.9%

FT

Direct Sequencing

Akagi et al. [17]

2009

Japan

52

7.7%

FFPE

Direct Sequencing

Kim et al. [21]

2016

Korea

534

10.5%

FFPE

Direct Sequencing

Phillips et al. [25]

2006

Australia

35

11.8%

FFPE

Direct Sequencing

Zheng et al. [33]

2016

China

79

19.7%

FT

Pyrosequencing

Shigaki et al. [27]

2013

China

219

21.0%

FT

Pyrosequencing

Liu et al. [23]

2017

China

210

22.9%

FFPE

Pyrosequencing

Baba et al. [18]

2015

Japan

440

23.0%

FFPE

Pyrosequencing

Yang et al. [31]

2017

China

24

4.2%

FFPE

NGS

Song et al. [28]

2014

China

158

4.5%

FT

NGS

Lin et al. [22]

2014

China

139

7.0%

FFPE

NGS

Gao et al. [19]

2014

Japan

133

9.0%

FT

NGS

Sawada et al. [26]

2016

Japan

144

10.4%

FT

NGS

TCGA et al. [9]

2017

Western and Eastern

90

13.0%

FT

NGS

Yokota et al. [37]

2018

Japan

126

13.5%

FFPE

NGS

Zhang et al. [32]

2015

China

90

17.0%

FT

NGS

Wang et al. [29]

2015

USA

71

24.0%

FFPE

NGS

NGS – next generation sequencing; FFPE – formalin-fixed paraffin-embedded tissue; FT – fresh frozen tissue

The PIK3CA gene is often mutated in several tumors types and most of its mutations occur in hotspot regions, such as E542K and E545A located in the helical domain (exon 9), and H1047R and H1047L in the kinase domain (exon 20) [11]. These mutations lead to the activation of the PIK3 pathway and have a great potential in oncogenic activities [11]. Interestingly, most of these mutations (E545A, H1047R and H1047L) occurred in patients in the CM/ESCC group and only one (E545A) in one patient in the ESCC group. We also identified other previously described important mutations (Table 3), the D549H mutation observed in the CM/ESCC group was reported in vulva and hepatocellular cancer [34]; R524K mutation found in the ESCC group was reported in colorectal cancer [35]; and the R555K mutation was reported in ovary cancer [36]. Interestingly, it is important to note that we identified three mutations in exon 20 that have not yet been reported (A1027D and K1030R in CM/ESCC group; T1053K in CM group). All these mutations occurred in patients with chagasic megaesophagus whose mutational profile of PIK3CA was never reported.

Importantly, we observed that CM/ESCC patients harboring PIK3CA mutations were associated with lower overall survival, suggesting its role as a prognostic biomarker in this group of patients. Interestingly, the results of our analyzes of the survival of the mutated patients differ from those reported by others studies, especially in regions of some risk such as Asia, in which patients with ESCC with mutations of the PIK3CA gene had a favorable overall survival compared to patients wild-type [37].

Notably, inhibitors of the PIK3-Akt-mTOR pathway have been developed as cancer target therapy alternatives, and patients harboring PIK3CA gene mutations could be potential candidates for such therapeutic approach [14]. Interestingly, phase I and II clinical trials using pan-PIK3CA agents (PIK3-class I), such as buparlisib (BKM120), an oral agent that affects α, β, γ and δ isoforms of PI3K [38], showed efficacy in several solid tumors, including head and neck cancer [39]. Copanlisib (BAY80–6946), an intravenous agent that affects α and δ isoforms of PI3K, also showed promising results in non-Hodgkin’s lymphomas [40]; as well as pictilisib (GDC-0941), an oral agent that affects γ and δ isoforms of PI3K, where a good response was reported in breast, colorectal, ovarian and non-small cell lung cancer [41]. Therefore, we can hypothesize that a subset of ESCC and CM/ESCC patients with PIK3CA mutations may benefit from these targeted-therapies and consequently improve their dismal survival.

In conclusion, this is the first study that analyzed and identified PIK3CA activating mutations in patients with esophageal squamous cell carcinomas associated with chagasic megaesophagus (CM/ESCC), which were associated with a worse outcome. Moreover, the identification of mutations in benign chagasic megaesophagus suggests their putative role in the etiology of esophageal squamous cell carcinoma and opens new opportunities for the treatment of these neglected patients with targeted-therapies.

Abbreviations

CM: 

Chagasic megaesophagus

ESCC: 

Esophageal squamous cell carcinoma

FFPE: 

Formalin-fixed paraffin-embedded

MSI: 

Microsatellite instability

PCR: 

Polymerase chain reaction

Declarations

Funding

This study was financially supported by CAPES and FAPESP - Fundação de Amparo à Pesquisa do Estado de São Paulo [Grant number 2015/20077–3 to FFM] and Barretos Cancer Hospital internal research funds (PAIP).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

FFM participated in the conception of the study, data collection, analysis and interpretation of the results, and draft of the manuscript. ACC, CFL, ATTO, CSN, SRMS, EC, SJA, MAMR and MACAH participated in the acquisition and quality assessment of the data collection and results interpretation. ALF and DPG participated in the, data collection, analysis and interpretation and draft of the manuscript. RMR participated in the designed, supervision, data interpretation and drafting and final revision of the manuscript. All authors gave final approval of the manuscript.

Ethics approval and consent to participate

The local ethic committees approved the study (number 1010/2015).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests for this present study.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, Barretos, SP, CEP 14784 400, Brazil
(2)
Department of Digestive Surgery, Barretos Cancer Hospital, Barretos, SP, Brazil
(3)
Department of Pathology, Diagnosis of Biopsies and Surgical Specimens, Barretos Cancer Hospital, Barretos, SP, Brazil
(4)
Department of Digestive Surgery and Pathology, Medical School, UFTM – Federal University of Triangulo Mineiro, Uberaba, Minas Gerais, Brazil
(5)
Departament of Gastroenterology Surgery and Pathology, Medical School, UNESP, São Paulo State University, Botucatu, SP, Brazil
(6)
Department of Endoscopy, Barretos Cancer Hospital, Barretos, SP, Brazil
(7)
Department of Radiology and Oncology, Medical School, USP - University of São Paulo, São Paulo, Brazil
(8)
Medical Laboratory of Medical Investigation (LIM) 14, Department of Pathology, Medical School, USP - University of São Paulo, São Paulo, Brazil
(9)
Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal
(10)
ICVS/3B’s - PT Government Associate Laboratory, Braga/Guimarães, Portugal

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.View ArticleGoogle Scholar
  2. Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048.View ArticleGoogle Scholar
  3. Prabhu A, Obi KO, Rubenstein JH. The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis. Am J Gastroenterol. 2014;109:822–7.View ArticleGoogle Scholar
  4. Tustumi F, Bernardo WM, da Rocha JRM, Szachnowicz S, Seguro FC, Bianchi ET, Sallum RAA, Cecconello I. Esophageal achalasia: a risk factor for carcinoma. A systematic review and meta-analysis. Dis Esophagus. 2017;30:1–8.View ArticleGoogle Scholar
  5. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375:1388–402.View ArticleGoogle Scholar
  6. Pandolfino JE, Gawron AJ. Achalasia: a systematic review. JAMA. 2015;313:1841–52.View ArticleGoogle Scholar
  7. Lacerda CF, Cruvinel-Carloni A, de Oliveira AT, Scapulatempo-Neto C, Lopez RV, Crema E, Adad SJ, Rodrigues MA, Henry MA, Guimaraes DP, Reis RM. Mutational profile of TP53 in esophageal squamous cell carcinoma associated with chagasic megaesophagus. Dis Esophagus. 2017;30:1–9.View ArticleGoogle Scholar
  8. Campanella NC, Lacerda CF, Berardinelli GN, Abrahao-Machado LF, Cruvinel-Carloni A, De Oliveira ATT, Scapulatempo-Neto C, Crema E, Adad SJ, Rodrigues MAM, et al. Presence of microsatellite instability in esophageal squamous cell carcinoma associated with chagasic megaesophagus. Biomark Med. 2018;12:573–82.View ArticleGoogle Scholar
  9. Cancer Genome Atlas Research N, Analysis Working Group: Asan U, Agency BCC, Brigham, Women’s H, Broad I, Brown U, Case Western Reserve U, Dana-Farber Cancer I, Duke U, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541:169–75.View ArticleGoogle Scholar
  10. Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170:605–35.View ArticleGoogle Scholar
  11. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 2006;94:455–9.View ArticleGoogle Scholar
  12. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.View ArticleGoogle Scholar
  13. Berenjeno IM, Pineiro R, Castillo SD, Pearce W, McGranahan N, Dewhurst SM, Meniel V, Birkbak NJ, Lau E, Sansregret L, et al. Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling. Nat Commun. 2017;8:1773.View ArticleGoogle Scholar
  14. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257–62.View ArticleGoogle Scholar
  15. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz S Jr, Duval A, Carneiro F, Machado JC, Hamelin R, Seruca R. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005;41:1649–54.View ArticleGoogle Scholar
  16. World Health Organization. Neglected tropical diseases, hidden successes, emerging opportunities. Geneva: WHO Library Cataloguing-in-Publication; 2009.Google Scholar
  17. Akagi I, Miyashita M, Makino H, Nomura T, Hagiwara N, Takahashi K, Cho K, Mishima T, Ishibashi O, Ushijima T, et al. Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma. Int J Oncol. 2009;34:767–75.View ArticleGoogle Scholar
  18. Baba Y, Ishimoto T, Harada K, Kosumi K, Murata A, Miyake K, Hiyoshi Y, Kurashige J, Iwatsuki M, Iwagami S, et al. Molecular characteristics of basaloid squamous cell carcinoma of the esophagus: analysis of KRAS, BRAF, and PIK3CA mutations and LINE-1 methylation. Ann Surg Oncol. 2015;22:3659–65.View ArticleGoogle Scholar
  19. Gao YB, Chen ZL, Li JG, Hu XD, Shi XJ, Sun ZM, Zhang F, Zhao ZR, Li ZT, Liu ZY, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet. 2014;46:1097–102.View ArticleGoogle Scholar
  20. Hou J, Jiang D, Zhang J, Gavine PR, Xu S, Liu Y, Xu C, Huang J, Tan Y, Wang H, et al. Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma. Hum Pathol. 2014;45:352–8.View ArticleGoogle Scholar
  21. Kim HS, Lee SE, Bae YS, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Shin SK, Lee SK, et al. PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. Oncotarget. 2016;7:30691–701.PubMedPubMed CentralGoogle Scholar
  22. Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X, Sato Y, Okuno Y, Varela AM, Ding LW, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet. 2014;46:467–73.View ArticleGoogle Scholar
  23. Liu SY, Chen W, Chughtai EA, Qiao Z, Jiang JT, Li SM, Zhang W, Zhang J. PIK3CA gene mutations in northwest Chinese esophageal squamous cell carcinoma. World J Gastroenterol. 2017;23:2585–91.View ArticleGoogle Scholar
  24. Mori R, Ishiguro H, Kimura M, Mitsui A, Sasaki H, Tomoda K, Mori Y, Ogawa R, Katada T, Kawano O, et al. PIK3CA mutation status in Japanese esophageal squamous cell carcinoma. J Surg Res. 2008;145:320–6.View ArticleGoogle Scholar
  25. Phillips WA, Russell SE, Ciavarella ML, Choong DY, Montgomery KG, Smith K, Pearson RB, Thomas RJ, Campbell IG. Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. Int J Cancer. 2006;118:2644–6.View ArticleGoogle Scholar
  26. Sawada G, Niida A, Uchi R, Hirata H, Shimamura T, Suzuki Y, Shiraishi Y, Chiba K, Imoto S, Takahashi Y, et al. Genomic landscape of esophageal squamous cell carcinoma in a Japanese population. Gastroenterology. 2016;150:1171–82.View ArticleGoogle Scholar
  27. Shigaki H, Baba Y, Watanabe M, Murata A, Ishimoto T, Iwatsuki M, Iwagami S, Nosho K, Baba H. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin Cancer Res. 2013;19:2451–9.View ArticleGoogle Scholar
  28. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91–5.View ArticleGoogle Scholar
  29. Wang K, Johnson A, Ali SM, Klempner SJ, Bekaii-Saab T, Vacirca JL, Khaira D, Yelensky R, Chmielecki J, Elvin JA, et al. Comprehensive genomic profiling of advanced esophageal squamous cell carcinomas and esophageal adenocarcinomas reveals similarities and differences. Oncologist. 2015;20:1132–9.View ArticleGoogle Scholar
  30. Wang WF, Xie Y, Zhou ZH, Qin ZH, Wu JC, He JK. PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients. Acta Pharmacol Sin. 2013;34:1560–7.View ArticleGoogle Scholar
  31. Yang JW, Choi YL. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-basis for precision medicine. Pathol Res Pract. 2017;213:836–41.View ArticleGoogle Scholar
  32. Zhang L, Zhou Y, Cheng C, Cui H, Cheng L, Kong P, Wang J, Li Y, Chen W, Song B, et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am J Hum Genet. 2015;96:597–611.View ArticleGoogle Scholar
  33. Zheng H, Wang Y, Tang C, Jones L, Ye H, Zhang G, Cao W, Li J, Liu L, Liu Z, et al. TP53, PIK3CA, FBXW7 and KRAS mutations in esophageal Cancer identified by targeted sequencing. Cancer Genomics Proteomics. 2016;13:231–8.PubMedGoogle Scholar
  34. Watkins JC, Howitt BE, Horowitz NS, Ritterhouse LL, Dong F, MacConaill LE, Garcia E, Lindeman NI, Lee LJ, Berkowitz RS, et al. Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA. Mod Pathol. 2017;30:448–58.View ArticleGoogle Scholar
  35. Berg M, Danielsen SA, Ahlquist T, Merok MA, Agesen TH, Vatn MH, Mala T, Sjo OH, Bakka A, Moberg I, et al. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS One. 2010;5:e13978.View ArticleGoogle Scholar
  36. Niskakoski A, Kaur S, Renkonen-Sinisalo L, Lassus H, Jarvinen HJ, Mecklin JP, Butzow R, Peltomaki P. Distinct molecular profiles in lynch syndrome-associated and sporadic ovarian carcinomas. Int J Cancer. 2013;133:2596–608.PubMedGoogle Scholar
  37. Yokota T, Serizawa M, Hosokawa A, Kusafuka K, Mori K, Sugiyama T, Tsubosa Y, Koh Y. PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue. BMC Cancer. 2018;18:826.View ArticleGoogle Scholar
  38. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012;11:317–28.View ArticleGoogle Scholar
  39. Soulieres D, Faivre S, Mesia R, Remenar E, Li SH, Karpenko A, Dechaphunkul A, Ochsenreither S, Kiss LA, Lin JC, et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2017;18:323–35.View ArticleGoogle Scholar
  40. Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. Ann Oncol. 2016;27:1928–40.View ArticleGoogle Scholar
  41. Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, Clarke PA, Raynaud FI, Levy G, Ware JA, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21:77–86.View ArticleGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us